why choose us

First received: June 30, 2022

Clinical Trial: 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Study Status: Completed

Recruit Status: RECRUITING

Condition: Tobacco Use Disorder

Study Type: INTERVENTIONAL


Official Title: 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Brief Summary: This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation.Three sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU).The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral…

Read more